Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Drug Testing: Special Populations and Additional Considerations in Addiction Treatment Webinar (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    This webinar will help to build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document. The development of the document guides provider decisions about drug testing, as no universal standard exists today.

    This webinar will help to build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document. The development of the document guides provider decisions about drug testing, as no universal standard exists today. It will also allow patients and their families, healthcare administrators, and payers determine clearly what is appropriate practice and what is considered outside the realm of appropriate practice in regards to drug testing in clinical addiction medicine. 

    JoAn Laes

    MD

    JoAn Laes, MD, Attending Physician, Division of Addiction Medicine, Hennepin County Medical Center, Minneapolis, MN; Core Medical Toxicology Faculty, Minnesota Poison Control System, Minneapolis, MN; Medical Director, Mission Detox Center, Plymouth, MN and 1800 Detox, Minneapolis, MN, ASAM Medical Toxicology workgroup Chair.Dr. Laes' practice is focused on inpatient addiction medicine and toxicology consultation and outpatient treatment of opioid and other substance use disorders. She is board certified in Internal Medicine, Addiction Medicine, and Medical Toxicology. She completed internal medicine residency at Hennepin County Medical Center and medical toxicology fellowship at Regions Hospital in St. Paul, Minnesota.

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Learning Objectives

    • Identify the unique considerations in drug testing for special populations including adolescents and pregnant women. 
    • Summarize the consensus document's recommendations for drug testing for special populations and discuss how they should be used in practice.
    • Analyze the importance of practitioner documentation, confidentiality, language and attitude in addiction treatment.
    • Determine how to appropriately conduct drug testing on-site and/or choose a qualified laboratory.
  • Drug Testing: Process and Settings in Addiction Treatment Webinar (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    This webinar will help build knowledge of the process and settings of drug testing in addiction treatment, as stated in The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document.

    image


    This webinar will help build knowledge of the process and settings of drug testing in addiction treatment, as stated in The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document. It will allow physicians to determine clearly how to choose and schedule a test, and respond to test results. It will also allow physicians to recognize the specific guidance warranted by different settings and levels of care including early intervention, outpatient services, intensive outpatient/partial hospitalization services, residential/inpatient care, medically management intensive inpatient services, and opioid treatment services. This webinar is intended for addiction specialists and all providers utilizing drug testing in the context of the identification, diagnosis, treatment, and monitoring of patients with, or at risk for, addiction. It will also be useful for physicians and other providers concerned about the possibility of addiction in their patient population. 

    Ken Freedman

    MD, MS, MBA, DFASAM

    Since 2009, Dr. Freedman has worked as the Chief Medical Officer of Lemuel Shattuck Hospital in Boston; a facility that cares for many patients with substance use disorder, previously serving as Chief of Medicine. In addition, he is also a Clinical Professor of Medicine at Tufts University School of Medicine and Adjunct Clinical Associate Professor of Psychiatry at the University of Massachusetts Medical School. Dr. Freedman is board-certified in addiction medicine, internal medicine, and gastroenterology, and a member of the AMA, ACP, and AGA. He has been a member of ASAM since 1997.

    Over the past 20 years, Dr. Freedman has used his wide range of clinical and managerial skills to serve the needs of behavioral health and substance use patients. He teaches clinicians on the medically appropriate and humane treatment of pain disorders. Dr. Freedman’s professional commitment is to help move health care delivery towards the integration of medical care and substance use treatment in respectful and innovative ways. 

    ACCME Accreditation Statement
    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


    AMA Credit Designation Statement
    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Learning Objectives 
    1. Identify the fundamental components of the process of drug testing in addiction treatment. 
    2. Determine how to appropriately select the type of test for each patient, and how to respond to various test results. 
    3. Analyze the importance of and guidance around test scheduling and frequency. 
    4. Recognize the specific guidance warranted by drug testing in different settings and levels of care. 

  • The ASAM Review Course in Addiction Medicine 2017 (20.5 CME)

    Contains 25 Product(s)

    The ASAM Review Course in Addiction Medicine is widely recognized as the essential primer for physicians and clinicians preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.

    Overview

    The ASAM Review Course in Addiction Medicine is widely recognized as the essential primer for physicians and clinicians preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.

    The course offers two and a half days of sessions which are mapped to the addiction medicine exam blueprint of topics for the exam and features an outstanding faculty. Over 800 professionals attend this popular course each time it is offered. ASAM’s Review Course has had a major impact on advancing a common base of scientific knowledge among physicians and other healthcare professionals.

    Learning Objectives:

    Upon completion, participants should be able to:

    • Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting
    • Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals
    • Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders
    • Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient
    • Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse


    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

     

    The ASAM CME Committee and Reviewers Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO, Chair

    None

     

     

    Catherine Friedman, MD

    Vice Chair

    None

     

      

    Noel Ilogu, MD, MRCP, DFASAM

    None

     

     

    Hebert L. Malinoff, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO

    Indivior

    BDSI

    Honorarium

    Honorarium

    Speaker

    Consultant/Speaker

     

    The ASAM Review Course Program Planning Committee Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Petros Levounis, MD, MD, DFASAM

    None

     

     

    Abigail Herron, DO, DFASAM, FAPA

    None

     

     

    Timothy K. Brennan, MD, MPH, FASAM

    None

     

     

    David Galbis-Reig, MD, DFASAM

    Abbot Pharmaceuticals

     

    AbbVie

     

     

    Cortex Pharmaceuticals

     

    GW Pharmaceuticals

     

    Hospira

     

     

    Pfizer, INC

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Stock Options

     

     

    Stock Options

    (spouse)

     

    Stock Owned through IRA Rollover Account

    Stock Owned through IRA Rollover Account

    Stock Options

    (Spouse)

     

    Bonds in IRA

    Carla Marienfield, MD

    None

     

     

    Ricardo Restrepo, MD, MPH

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Erin Zerbo, MD

    None

     

     

     

    The ASAM Review Course Faculty Member Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Petros Levounis, MD, MD, DFASAM

    None

     

     

    Abigail Herron, DO, DFASAM, FAPA

    None

     

     

    Timothy K. Brennan, MD, MPH, FASAM

    None

     

     

    Jeffrey DeVido, MD, MTS

    Philip Morris

     

     

    Altria

    Ownership Interest

     

    Ownership Interest

    Equity Shareholder

     

    Equity Shareholder

    Paul H. Earley, MD, DFASAM

    Alkermes

     

    Georgia PHP, INC

     

    Earley Counsultancy, LLC

     

    DynamiCare Health, INC

    Honoraria

     

    Salary

     

     

    Salary

     

     

     

    Salary

    Speaker

     

    Medical Director

     

     

    Principal

     

     

     

    Speaker

    James W. Finch, MD, DFASAM

    Orexo Pharmaceuticals

     

    Indivior Pharmaceuticals

    Honoraria

     

     

    Honoraria

    Speaker

     

     

    Speaker

    Marc Fishman, MD, DFASAM

    Alkermes

     

     

    US WorldMeds

     

     

     

     

    MediaRez

    Salary

     

     

    Salary

     

     

     

     

    Research Funding

    Consultant; Advisory Board

     

    Consultant; Advisory Board; Principal Research Investigator

     

    Principal Research Investigator

    David Galbis-Reig, MD, DFASAM

    Abbot Pharmaceuticals

     

    AbbVie

     

     

    Cortex Pharmaceuticals

    GW Pharmaceuticals

     

    Hospira

     

     

    Pfizer, Inc

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Stock Options

     

     

    Stock Options

    (spouse)

    Stock Owned through IRA Rollover Account

    Stock Owned through IRA

     

    Rollover Account

    Stock Options

    (Spouse)

    Bonds in IRA

    Leslie Hayes, MD

    None

     

     

    Carla Marienfield, MD

    None

     

     

    Ricardo Restrepo, MD, MPH

    None

     

     

    Richard Ries, MD, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Sharon Stancliff, MD

    None

     

     

    Timothy J. Wiegand, MD, FACMT, FAACT, FASAM

    None

     

     

    Erin Zerbo, MD

    None

     

     

    ACCME Accreditation Statement:

    The American Society of Addiction Medicine is accredited by the Accreditation Council for
    Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement:

    The American Society of Addiction Medicine designates this live activity for a maximum of 20.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Academy of Family Physicians: 

    This Live activity, The 2017 ASAM Review Course in Addiction Medicine & Pre-Courses, with a beginning date of 07/26/2017, has been reviewed and is acceptable for up to 27.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification Program (Tmoc)

    This course has been approved by The American Board of Addiction Medicine (ABAM).  Physicians enrolled in the Transitional Maintenance of Certification (Tmoc) Program can apply a maximum of 20.5 AMA PRA Category 1 Credits

    Upon completion, participants should be able to:

    • Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting
    • Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals
    • Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders
    • Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient
    • Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse

    The ASAM Review Course in Addiction Medicine provides an up-to-date review of the core content of addiction medicine for:

    • Physicians preparing for the ABPM Board Certification/Recertification Examination in addiction medicine
    • Addiction specialists seeking a "refresher" course that incorporates recent developments in addiction science and practice
    • Non-specialist physicians and other healthcare professionals needing the knowledge to identify and manage problems related to substance use disorders for their patients 
  • Pain Management and Opioids: Balancing Risks and Benefits Live Webinar - July 25, 2018 (2.5 CME)

    Contains 5 Component(s), Medical Credits Offered

    Review prescribing habits and examine the difference between extended release/long acting medications to help ensure patient safety and effective pain management.

    image

    The misuse of extended-release and long-acting (ER/LA) opioids is a major public health problem. Centers for Disease Control and Prevention reported the following:

    • From 2000 to 2015 more than half a million people died from drug overdoses.
    • 91 Americans die every day from an opioid overdose.

    The CO*RE/ASAM Pain Management and Opioids: Balancing Risks and Benefits addresses the opioid public health crisis. This comprehensive course was developed by renowned experts from Collaborative for REMS Education (CO*RE) and incorporates all six units outlined in FDA blueprint for safe opioid prescribing. The updated course also provides necessary context for safe opioid prescribing by discussing biopsychosocial aspects of pain, the newest clinical guidelines on the treatment of chronic pain, and state policies about prescribing opioids.

    Learners will be able to:

    • Accurately assess patients with pain for consideration of an opioid trial
    • Establish realistic goals for pain management and restoration of function
    • Initiate opioid treatment (IR and ER/LA) safely and judiciously, maximizing efficacy while minimizing risks
    • Monitor and re-evaluate treatment continuously; discontinue safely when appropriate
    • Counsel patients and caregivers about use, misuse, abuse, diversion, and overdose
    • Educate patients about safe storage and disposal of opioids
    • Demonstrate working knowledge and ability to access general and specific information about opioids, especially those used in your practice.

    CME Information and Disclosure Listing

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

     

    The American Society of Addiction Medicine designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the Medical Education Council, the CME Committee, program planning committees and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of the activity. All program planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the program planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

     

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine R. Friedman, MD, FAPA, DFASAM, Chair

    None

     

     

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM

    None

     

     

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO

    None

     

     

    Zwaantje Hamming, FNP-C, CARN-AP

    None

     

     

    Noel Ilogu, MD, MRCP, DFASAM

    None

     

     

    Hebert L. Malinoff, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    ASAM Staff and Consultants:

     

     

     

    Arlene C. Deverman, MA, CAE, CFRE

    None

     

     

    Marcia Jackson PhD

    None

     

     

    Sandy Metcalfe

    None

     

     

     

    Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Herbert Malinoff, MD, FACP, DFASAM

    None

     

     

    Yngvild Olsen, MD, MPH

    None

     

     

    Theodore Parran, MD, FACP

    None

     

     

    Edwin Salsitz, MD, DFASAM

    None

     

     

    R. Corey Waller, MD, MS, FACEP

    None

     

     

     

    Faculty

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

     

     

    ASAM CME Committee Reviewers

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Jacob Bobrowski, MD, FAAFP

    None

     

     

    Anthony H. Dekker, DO, DFASAM

    None

     

     

     

    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DipABAM, DFASAM, Chair

    Pfizer

    Johnson & Johnson

    Pfizer Canada

    Grant funding

    Consulting Fees

    Consulting Fees

     Principal Investigator

    Consulting

    Consulting

    Daniel Alford, MD, MPH

    None

     

     

    Michael Fingerhood, MD, FACP, FASAM

    None

     

     

    Catherine R. Friedman, MD, FAPA, DFASAM

    None

     

     

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO

    None

     

      

    Miriam S. Komaromy, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Mark P. Schwartz, MD, DFASAM

    None

     

     

    Mark A. Weiner, MD, FASAM

    None

     

     

    ASAM Staff and Consultants:

     

     

     

    Arlene C. Deverman, MA, CAE, CFRE

    None

     

     

    Marcia Jackson PhD

    None

     

     

    Jennifer L. Butchart

    None

     

     

    Penny S. Mills, MBA

    None

     

     

     

    Acknowledgement

    Presented by ASAM, a member of the Collaborative on REMS Education (CO*RE), 10 interdisciplinary organizations working together to improve pain management and prevent adverse outcomes.

    RPC Commercial Support Disclosure Statement

    This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see this link for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.

    This course is not intended to advocate for the use of ER/LA Opioids, but to ensure proper education about safe prescribing practices should a medical provider determine that ER/LA Opioids are the best course of treatment.

  • The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine Webinar (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    This webinar helps build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document, which guides provider decisions about drug testing, as no universal standard exists today.

    image


    This webinar helps build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document, which guides provider decisions about drug testing, as no universal standard exists today. It will allow providers, patients and their families, healthcare administrators, and payers determine clearly what is appropriate practice and what is considered outside the realm of appropriate practice in regard to drug testing in clinical addiction medicine. This webinar is primarily intended for addiction specialists and all providers utilizing drug testing in the context of the identification, diagnosis, treatment, and monitoring of patients with, or at risk for, addiction. It will also be useful for physicians and other providers concerned about the possibility of addiction in their patient population.


    Louis E. Baxter, Sr.

    MD, DFASAM

    Dr. Louis E. Baxter, Sr., MD, DFASAM is a Past ASAM President and is the President &CEO of thr Professional Assistance Program of New Jersey, Inc.

    Dr. Baxter is a certified in Addiction Medicine by the American Board of Addiction Medicine and formerly served on the Board of Directors. Dr. Baxter has served and chaired many government advisory committees and panels which include SAMHSA, NIDA, CSAT, NIAAA, and a Presidential Advisor through ONDCP since the Clinton Administration.

    Dr. Baxter has served the State of New Jersey in various capacities serving on the Governor's Council for Drug and Alcohol Addiction, Medical Director for the Division of Addiction Services, and most recently as the Addiction Medicine Consultant for the Division of Mental Health and Addiction Services. He has held academic appointments as Assistant Clinical Professor of Medicine for former University Medicine & Dentistry and now currently with Rutgers New Jersey Medical School in Newark, NJ. Dr. Baxter is serving as Co-Director if the Addiction Medicine Fellowship Program at Howard University Medical School and Hospital.

    Upon completion of this activity, participants should be able to:
    -Recognize the importance of the guidance needed around drug testing today
    -Identify the fundamental components of drug testing in a clinical setting
    -Summarize the document's recommendations and discuss how they should be used in practice
    -Address common clinical questions around drug testing in a clinical setting

  • Research-Based Clinical Strategies to Prevent and Address Adolescent Substance Use and Prescription Medication Misuse: Being Part of the Solution

    Contains 4 Component(s)

    This activity has been designed to meet the educational needs of clinicians including, physicians, physician assistants, nurse practitioners, nurses, and dentists/oral maxillofacial surgeons, involved in the care of adolescent patients.

    image

    ASAM is part of a collaboration that made this course possible.

    Educational Objectives

    After completing this activity, the participant should be better able to:

    Part 1

    • Describe the prevalence of substance use and prescription drug misuse among adolescents
    • Explain why adolescents are at high risk of developing a substance use disorder and how clinicians can help prevent it
    • Demonstrate strategies to build trust with adolescent patients and ensure confidentiality when addressing substance use and prescription drug misuse
    • Summarize ways to identify substance use and prescription drug misuse in adolescent patients, including determining their level of risk

    Part 2

    • Discuss strategies to address substance use and prescription drug misuse in adolescent patients based on their level of use
    • Summarize when and how to follow up with adolescent patients who use substances or misuse prescription drugs

    Joint Accreditation Statement

    In support of improving patient care, this activity has been pl

    image

    anned and implemented by the Postgraduate Institute for Medicine and National Institute for Drug Abuse.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This activity has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 06/30/2017. Term of approval is for one year from this date.

    This continuing medical education activity has been reviewed by the American Academy of Pediatrics and is acceptable for a maximum of 1.00 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics.

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

    American Dental Association CERP Recognition

    This continuing education activity has been planned and implemented in accordance with the standards of the ADA Continuing Education Recognition Program (ADA CERP) through joint sponsorship efforts between Postgraduate Institute for Medicine and the National Institute for Drug Abuse.

    Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education.  ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of the credit hours by boards of dentistry.

    Postgraduate Institute for Medicine designates this activity for 1.0 continuing education credit.

    Education Coalition

    This activity was developed by an education Coalition of experts and medical professional organization representatives. The Coalition comprises the following organizations and experts:

    Type of Reviewer: Organization/ Expert Consultant

    Reviewer Name

    California Academy of Family Physicians (CAFP)

    Cynthia Kear, Senior Vice President

    American Society of Addiction Medicine (ASAM)

    Jennifer Butchart, Specialist, Professional Development  
    Penny S. Mills, MBA, Executive Vice President / CEO     
    Arlene C. Deverman, CAE, Chief Learning Officer

    American Osteopathic Association (AOA)

    Stephanie Townsell, Public Health Project Manager

    Marla Kushner, DO

    American Association of Nurse Practitioners (AANP)

    Anne Norman, DNP, APRN, FNP-BC, Associate Vice President of Education

    American Academy of Pediatrics (AAP)

    Renee Jarrett, Manager, Mental Health and Foster Care Initiatives Div of Developmental Pediatrics and Preventive Services

    American Academy of Physician Assistants (AAPA)

    Daniel Pace, Vice President, Education
    Marie-Michele Leger, MPH, PA-C, Director, Clinical Education Sara Evans, PMP, Project Manager, Quality Improvement Initiatives

    American Association of Oral and Maxillofacial Surgeons (AAOMS)

    Vincent DiFabio, DDS

    Consultant

    Samantha Mattiucci, PharmD, CHCP, Director of Medical Education

    Consultant

    Jan Schultz, BSN, MSN, RN, CHCP, Director of Education Outcomes and Accreditation Services

    Consultant

    Dan Alford, MD, Associate Professor of Medicine, Assistant Dean and Program Director of the Addiction Medicine Residency program at Boston University School of Medicine

    Consultant

    Sharon Levy, Director, Adolescent Substance Abuse Program (ASAP)Assistant Professor in Pediatrics,  Boston Children's Hospital

    Consultant

    Jeff Baxter, MD, Assistant Professor Department of Family Medicine and Community Health, University of Massachusetts Medical School

    Consultant

    Marc Fishman, MD

    Consultant

    Carol Havens, MD

    Disclosure of Conflicts of Interest

    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    The Education Coalition members reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Marc Fishman, MD discloses the following: Consulting Fees: US World Meds; Contracted Research: Media Rez, US World Meds

    Ownership Interest: Maryland Treatment Centers

    The following Education Coalition members have nothing to disclose: Cynthia Kear, Jennifer Butchart, Penny Mills, Arlene Deverman, Stephanie Townsell, Marla Kushner, Anne Norman, Renee Jarrett, Daniel Pace, Marie-Michele Leger, Sara Evans, Vincent DiFabio, Jan Schultz, Dan Alford, Sharon Levy, Jeff Baxter, Marc Fishman, and Carol Havens

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

    The following National Institute on Drug Abuse planners and managers, Elisabeth Davis; Carol Krause; Josie Anderson; Jack Stein, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months

    The following JBS International, Inc. planners and managers, Candace Baker; Susan Hayashi; Laura Nolan; Bethel Arya; and Veronica Junghahn, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months

    For Physicians, Registered Nurses and Dentists, please follow the instructions below:

    PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. Go to CME University at: www.cmeuniversity.com and register or login
    2. Once logged in, click on “Find Post-test/Evaluation by Course” at the top of the page
    3. Type in 11118 (for Part1) or 12614 (for Part 2) in the box; hit enter
    4. Click on the activity title
    5. Complete the online posttest and evaluation and obtain your CME certificate to download and/or print for your files.

    Upon completion of the online posttest and evaluation form, you will have immediate access to a certificate of attendance to print or save for your files. You can save your certificate by selecting the “Save” option on the print screen. 

    For any questions relating to the physician, nursing or dentist accreditation, please contact PIM via:  inquiries@pimed.com

    For Nurse Practitioners follow the instructions below:

    • Visit the AANP’s Website (coming soon) to take the course for AANP credit.

    For Physician Assistants follow the instructions below:

    • Visit the AAPA’s Website to take the course for AAPA credit.

    For Doctors of Osteopathic Medicine follow the instructions below:

          Visit the AOA’s Website (coming soon) to take the course for AOA credit.

    Internet activity

    Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

  • Close The Gap: Pathways to the Addiction Medicine Exam

    Contains 3 Component(s), Medical Credits Offered

    Nearly 20.5 million Americans suffer from a substance use disorder (SUD), yet only 1 in 10 people with a substance use disorder (SUD) receive treatment. This treatment gap leaves millions without the proper treatment, expanding the addiction medicine workforce is vital. During this webinar, we will discuss how physicians can become board-certified in Addiction Medicine under the new medical subspecialty.

    The 60-minute webinar will provide insights into current addiction treatment gap and how physicians can close this gap by becoming board-certified in addiction medicine certified through the upcoming American Board of Preventive Medicine addiction medicine exam

    This webinar is targeted toward clinicians, physicians, academicians and other addiction medicine professionals looking to learn more the addiction treatment gap and the new addiction medicine subspecialty under the American Board of Preventive Medicine (ABPM). 

    The purpose of the webinar is to emphasize the need to close the current treatment gap and increase the addiction medicine workforce. There will be a key focus on the new addiction medicine subspecialty and the pathways for certification. There will be a live question and answer session during the webinar to address any concerns and foster conversation around this monumental development in the field. 

    • Addiction medicine specialists
    • Opioid treatment program providers
    • DATA-waived provider
    • Public health management services providers

    Upon completion of this activity, participants will be able to:

    •  Demonstrate the importance of the need for an expanded workforce.  
    •  Describe the different hurdles patients faces when seeking treatment for addiction treatment.
    •  Identify different demographics that are uniquely affected by the treatment gap.
    •  Diagram the different learning methods physicians can take to educate themselves in addiction medicine.
    •  Construct an outline of the different pathways physicians can take to become eligible to sit for the addiction medicine exam.
    •  Identify certain criteria physicians have to uphold in order to become an addiction specialist. 

    ACCME Accreditation Statement The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

     AMA Credit Designation Statement: The American Society of Addiction Medicine designates this live activity for a maximum of AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    ASAM 2017-2018 CME Committee Disclosure Information:

     

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, Chair

    None

     

     

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO

    None

     

      

    Noel Ilogu, MD, MRCP, DFASAM

    None

     

     

    Hebert L. Malinoff, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO

    Indivior

    BDSI

    Honorarium

    Honorarium

    Speaker

    Consultant/Speaker

     

    April 7, 2017 – April 2018


  • ASAM 48th Annual Conference - Innovations in Addiction Medicine and Science - 2017 (71 CME)

    Contains 57 Product(s)

    The nation’s premiere conference on the latest science, research, best practices and innovations in addiction medicine.

    The ASAM 48th Annual Conference is the nation’s premiere conference on the latest science, research, best practices and innovations in addiction medicine. The 2017 program includes more education offerings such as; seven concurrent sessions offerings at a time instead of six, three pre-conference courses instead of two.  There will also be three Plenary Sessions that include the popular Opening Plenary Session and Policy Plenary Session and new this year the National Perspectives Plenary Session moderated by the ASAM president with leaders from national federal agencies. There will be other exciting changes to provide learning in a more interactive, casual and fun environment. 

    Learning Objectives:

    At the conclusion of the conference, participants should be able to:

    • Identify and describe the new developments affecting the science, policy, and clinical practice of addiction medicine.
    • Compare presented clinical guidelines/best practices with the participant's current practice and identify strengths or gaps.
    • Analyze new research and science to develop practical applications for treatment or further research.
    • Explain recent or upcoming policy changes and identify implications or areas for provider involvement.
    • Create a network of professionals or a set of resources that can be used to support the participant's practice.


    Accreditation Council for Continuing Medical Education (ACCME)

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

    The ASAM 48th Annual Conference - Innovations in Addiction Medicine and Science

    The American Society of Addiction Medicine designates this enduring material for a maximum of 71 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification (Tmoc)

    This course has been approved by the American Board of Addiction Medicine (ABAM).  Physicians enrolled in the ABAM Transitional Maintenance of Certification (Tmoc) Program can apply a maximum of 71 AMA PRA Category 1 Credit(s)™ for completing the The ASAM 48th Annual Conference – Innovations in Addiction Medicine and Science.

    American Psychological Association (APA)

    The American Society of Addiction Medicine (ASAM) Continuing Medical Education (CME) has been approved for renewal of certification by the APA College of Professional Psychology. ASAM CME credits may be applied toward the APA’s “Certificate of Proficiency in the Treatment of Alcohol and Other Psychoactive Substance Use Disorders.”

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    CME Committee Members

    • Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO, Chair
    • Catherine Friedman, MD, FASAM, Vice-Chair
    • Noel Ilogu, MD, MRCP, FASAM
    • Herbert L. Malinoff, MD, FACP, DFASAM
    • Edwin A. Salsitz, MD, DFASAM
    • John C. Tanner, DO, CCFC, DFASAM

    Staff - Sandy Metcalfe, Consultant, ASAM CME Committee, Professional Development Department

    CME Committee, Program Planning Committee and Faculty Disclosure Information

    In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These polices include resolving all conflicts of interest between the CME Committee, planning committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    Who Should Attend:

    • Physicians and Clinicians
    • Researchers and Academics
    • Counselors and Students
    • Other Health Care Professionals 

    dedicated to increasing access and improving the quality of addiction treatment and care.

  • Evaluating Drug Dependence: Regulatory, Methodological and Clinical Challenges (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    Evaluating drug withdrawal effects is an integral component of dependence potential, which informs the overall safety, appropriate dosing, and scheduling of a drug. Understanding withdrawal phenomenon is critical in the care and management of patients who are physically dependent on medication or drugs of abuse. This workshop will address the regulatory and methodological considerations that are rapidly evolving in this active area of research and will cover case examples of studies examining drug withdrawal and dependence. In addition, the clinical relevance of dependency and mitigation of symptoms in the clinical setting will be discussed.

    Evaluating drug withdrawal effects is an integral component of dependence potential, which informs the overall safety, appropriate dosing, and scheduling of a drug. Understanding withdrawal phenomenon is critical in the care and management of patients who are physically dependent on medication or drugs of abuse. The methodological approaches to assess dependence continue to evolve and require careful evaluation of both preclinical and clinical data. Physical dependence can manifest from various drug classes including classes of drugs that are and are not associated with substance use disorder (e.g. beta blockers, corticosteroids). Preliminary approaches often include animal models to evaluate behavioral and physical manifestation of withdrawal, however translation to humans can be challenging. In the clinical setting, evaluation of withdrawal requires characterization of a drug's pharmacology to determine what type of symptoms may manifest upon abrupt discontinuation. Furthermore, rebound phenomenon resulting in a worsening of symptoms of the treated disease as a result of abrupt discontinuation, is also an important study assessment (Fontaine at et 1984). Study populations must be carefully considered, particularly in patient populations that cannot be safely withdrawn from study drug. Clinical trials must determine what population, duration of maintenance and endpoints are relevant for a given drug. For example, the time to establish dependence to a benzodiazepine can vary by drug type and dose and can range from 4 to 12 weeks (Mackinnon and Parker, 1982). Commonly adverse events and drug-specific withdrawal scales are included to evaluate withdrawal symptoms, however other pharmacodynamics measures may also be considered. The administration of endpoints and safety monitoring requires also practical considerations in the context of larger patient trials, where confined stays may not be possible following abrupt discontinuation. This workshop will address the regulatory and methodological considerations that are rapidly evolving in this active area of research and will cover case examples of studies examining drug withdrawal and dependence. In addition, the clinical relevance of dependency and mitigation of symptoms in the clinical setting will be discussed.

    Beatrice Setnik

    PhD

    Dr. Setnik has been working in the area of clinical drug development and abuse potential (AP) assessment since 2005.  Dr. Setnik is currently the Vice President of Clinical Pharmacology at INC Early Phase and an Adjunct Professor at the University of Toronto (Department of Pharmacology and Toxicology).  Dr. Setnik earned her doctorate degree in Pharmacology and the Collaborative Program in Neuroscience from the University of Toronto in 2005.  In her previous role as Senior Director, Clinical Sciences (King Pharmaceuticals and Pfizer, Inc), Dr. Setnik lead the clinical development, regulatory filing, and lifecycle management, including abuse potential evaluation, of several pain compounds including abuse deterrent opioid formulations. In her previous role as a Research Scientist (formerly Ventana / Decisionline Clinical Research, Toronto, Canada), Dr. Setnik was responsible for providing scientific input on various specialty phase I-II clinical trials including abuse potential studies for CNS drugs.   Dr. Setnik has published numerous research articles in internationally recognized peer-reviewed journals and has presented at several scientific meetings and conferences.  In addition, she chairs the clinical sub-team within the Cross Company Abuse Liability Council and has been an active member since 2008. Dr. Setnik is also an active member and participant in several congresses including the College on Problems of Drug Dependence. She has also been actively engaged in many aspects of abuse potential assessment including development of patient reported outcome instruments and contributing to post-marketing surveillance studies.

    Jack Henningfield

    PhD

    Dr. Henningfield was trained in abuse liability assessment and related sciences in the Psychopharmacology Program at the University of Minnesota and the Behavioral Biology Program of The Johns Hopkins University School of Medicine in the 1970s. In the 1980s and 90s, at the National Institute on Drug Abuse (NIDA), he served as Chief of the Clinical Pharmacology Branch, and the Abuse Potential Assessment Section and contributed to NIDA's drug scheduling recommendations. In 1996 he left NIDA to consult on these issues with Pinney Associates to pharmaceutical developers.Dr. Henningfield is proud to be a recipient of the 1996 ASAM Annual Award "for expanding the frontiers of the field of addiction medicine and broadening our understanding of the addictive process, through research and innovation." He has published more than 400 articles and books related to addiction and contributed to NIDA's abuse potential assessment monographs in the 1980s, FDA's first draft guidance in 1990, and expert reviews and special conferences on abuse potential in the 2000s leading to FDA's 2010 draft guidance and the 2017 Final Guidance. His decades of research, product evaluation and contribution to regulation provide his expert perspectives on the science base, the regulatory implications, and the overall value of the Final Guidance. This Guidance, along with FDA’s 2015 Guidance on Abuse-Deterrent Opioid is among FDA’s many efforts to more effectively address substance abuse and overdose by improving new drug product evaluation and labeling. He has long advocated for comprehensive drug control approaches that move us closer to achieving the goal espoused by former Surgeon General C. Everett Koop, who stated it as follows in a 2003 National Press Club address: “We must greatly expand our efforts to help those with addictions so that getting treatment will be as easy as getting addictive drugs.” (Military Medicine, 2003).

    Alicja Lerner

    MD, PhD

    Dr. Lerner has years of experience in neurology, neuroimaging and neuroscience research at NIH, University of Iowa and regulatory science at FDA.  At NIH (2000-2008) the activity included the clinical and research fellowships at NINDS and NIMH where she participated in the development of about half a dozen of clinical research protocols as a Principal Investigator and co-investigator. This research resulted in published papers on neural networks involved in the Tourette’s syndrome, dystonia and suppression of natural urges as shown by positron emission tomography (PET) research studies. During the PhD program at the Dept. of Anatomy and Cell Biology at the University of Iowa (1991-1996) her research was focused on the revealing anatomical complexities of the neural circuits connecting cerebellum, thalamus and basal ganglia. Since 2008 she works at FDA as medical officer at Controlled Substance Staff, CDER, and her particular interest is a development of the most effective ways to evaluate dependence and withdrawal in the clinical trials during the drug development.
    Dr. Lerner acquired the medical degree at Medical Academy, Warsaw, Poland, after which followed the internship in Poland, residency in anesthesiology in Germany, and residency in neurology in US, in North Carolina, and the fellowship in movement disorders and neuroimaging at NINDS, NIH.

    Pierre Geoffroy

    MDCM, MSc, FCFP, DABAM

    Pierre Geoffroy is Vice President of Early Phase Research at INC Research in Toronto, where he is involved in early phase clinical trials and human abuse liability studies. Trained in Emergency Medicine and Family Medicine at McGill University in Montreal, he has pursued a career in both clinical research and medicine, allowing him to apply practical experience to clinical research for nearly 25 years. He also holds a Master’s degree in epidemiology from McGill and an MSc in Nutrition from the University of Toronto. While having directed late stage drug development for many years in large pharma, he has been involved in early phase research in several CROs in both in Canada and Japan for over 10 years. Dr. Geoffroy is a fellow of the College of Family Physicians of Canada and is board-certified in Addiction Medicine. He is an actively practicing physician in Toronto in both family medicine and addiction medicine and has a keen interest in human abuse liability testing in recreational drug users and the development of new medicines to combat the growing addiction epidemic.

  • New Frontiers in the Treatment of Co-Occurring Alcohol Use Disorder and Anxiety (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    In this presentation, I will provide a critical review of two key assumptions that have driven much of the comorbidity research over the past 35 years (since the introduction of DSM III): that the various subtypes of anxiety disorder like social phobia each have a distinct relationship to alcohol use disorder and that alleviating a co-occurring anxiety disorder through conventional psychiatric treatments, either alone or in conjunction with AUD treatment, is the most effective clinical response to comorbidity.

    Anxiety disorders frequently co-occur with AUD, more than doubling the likelihood or relapse in the months following AUD treatment. In clinical samples, about 50% of AUD treatment patients can be diagnosed with a co-occurring anxiety disorder, and numerous community-based epidemiological samples show that alcohol dependence is two to four times more common among individuals with anxiety disorders. This symposium will highlight evidence indicating that the overall internalizing load (amount of negative affect), rather than the presence of any particular anxiety (or depressive) disorder, dictates risk for AUD. In addition, it will feature results from an NIAAA-sponsored RCT showing that augmenting AUD treatment with a cognitive-behavioral program designed to reduce drinking to cope improved alcohol outcomes to a significantly greater degree than did augmentation with treatment aimed at reducing anxiety. The symposium will also provide an overview of the rates of co-occurring alcohol use disorders (AUD) and posttraumatic stress disorder (PTSD) in the general population, as well as among active duty military personnel and military veterans. Challenges in treating this particular comorbidity will be briefly described, and an overview of the findings from the behavioral treatment outcome literature will be provided. Finally, commonalities in the neurobiology of PTSD and AUDs will be reviewed, with special emphasis on implications for the development of novel therapeutic targets. This will include an overview of pharmacotherapeutic trials informed by research on putative common PTSD/AUD pathways involving the noradrenergic system, the hypothalamic-pituitary-adrenal axis, and other systems involved in both addictive and anxiety disorders.

    Deidra Y. Roach

    MD

    Dr. Roach has more than 30 years of experience in the field of addiction treatment. She currently serves as a Program Director for the National Institute on Alcohol Abuse and Alcoholism where, among other responsibilities, she manages research portfolios addressing the treatment of co-occurring mental health and alcohol use disorders and alcohol-related HIV/AIDS among women. She also serves on the Interagency Coordinating Committee on Fetal Alcohol Spectrum Disorders (ICCFASD) and the NIH Coordinating Committee for Research on Women’s Health. Dr. Roach chairs the Women Drinking, and Pregnancy Work Group of the ICCFASD.

    Matt G. Kushner

    PhD

    Dr. Kushner has been a Professor in the Department of Psychiatry at University of Minnesota-Minneapolis since 1991 and has held the rank of full professor since 2006.  He obtained his B.A. in psychology and philosophy from the University of Nebraska in 1983, and his Ph.D. in clinical psychology in 1991 from University of Missouri – Columbia.  He completed an Internship in Clinical Psychology at the Medical College of Pennsylvania in 1991.   Dr. Kushner has studied the association of alcohol use disorders with co-occurring anxiety disorders for more than 25 years with continuous funding support for over 20 years from the US National Institutes of Health (NIH).  Dr. Kushner has also served as an NIH scientific review group member for the National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse .  He has published over 70 peer reviewed articles in journals such as The American Journal of Psychiatry, JAMA Psychiatry and Biological Psychiatry that, collectively, have been cited more than 5000 times.  He is the Director of an NIH post-doc training program (T32) and is the Principal Investigator on an ongoing NIH-funded project to develop and test specialized treatments for substance abusers with co-occurring psychiatric disorder.  In 2013 he was awarded the Dan Anderson Award for making unique and significant contributions to the field with the potential to change clinical practice in alcohol use disorders treatment.  He is a Minnesota Psychological Association Distinguished Scholar and a University of Missouri Distinguished Alumnus.

    Tracy Simpson

    PhD

    Tracy Simpson, PhD, is a Clinician Investigator with the Center of Excellence in Substance Abuse Treatment and Education at the VA Puget Sound Healthcare System. She is also an Associate Professor in the Department of Psychiatry and Behavioral Sciences, University of Washington. Her primary research areas include evaluating interventions for alcohol use disorders with and without co-occurring PTSD, mechanisms of behavior change, assessment methods, and women veterans' substance use and mental health. She provides clinical care for women veterans with PTSD and addiction and is actively engaged in mentoring junior faculty, post doctoral fellows, and clinical psychology interns.

    Kathleen T. Brady

    MD, PhD

    Kathleen T. Brady, MD, PhD is a Distinguished University Professor and Vice President for Research at the Medical University of South Carolina (MUSC). She received her PhD in Pharmacology from the Medical College of Virginia, Richmond, and her MD degree from tMUSC.  She is an experienced clinical and translational researcher and her research focuses on innovative treatments for drug and alcohol abuse/addiction, gender differences in addictions and comorbid conditions such as posttraumatic stress disorder and other anxiety disorders.  She has been continuously funded by NIH for over 30 years.